Monitoring the Response of Chemotherapy on Breast Cancer Tumors by Photon Migration Spectroscopy
Abstract
Optimal management of patients with locally advanced breast cancer (LABC) remains a complex therapeutic problem. LABC represents 5-20% of all newly diagnosed breast cancers in the United States with a higher incidence in medically underserved areas. Over the years, treatment for LABC has been evolving from radical mastectomy to the use of neoadjuvant chemotherapy followed with mastectomy or breast conservation therapy. The optimal intensity and duration of neoadjuvant chemotherapy for LABC still remains controversial due to the difficulty of evaluating response to therapy. Presently, response to treatment is measured by physical exam, mammography and or ultrasound. Several studies have showed significant discrepancies between the clinical assessment of response to neoadjuvant chemotherapy and the pathologic assessment of response found in post therapy surgical specimens. The goal of this project is to use Photon Migration Spectroscopy (PMS) as a new modality to monitor the response of breast tumor to neoadjuvant chemotherapy. PMS has shown excellent sensitivity to crucial early functional changes in breast tissue subjected to neoadjuvant chemotherapy which can be pivotal to the choice of chemotherapy agents and final survival outcome.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2003
- Accession Number
- ADA418087
Entities
People
- David J. Hsiang
Organizations
- University of California, Irvine